Cartesian Therapeutics (RNAC) EBT Margin (2016 - 2025)
Historic EBT Margin for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to 4318.14%.
- Cartesian Therapeutics' EBT Margin fell 4416600.0% to 4318.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 7674.79%, marking a year-over-year decrease of 72390400.0%. This contributed to the annual value of 198.23% for FY2024, which is 7197400.0% up from last year.
- Latest data reveals that Cartesian Therapeutics reported EBT Margin of 4318.14% as of Q3 2025, which was down 4416600.0% from 6732.55% recorded in Q2 2025.
- Cartesian Therapeutics' 5-year EBT Margin high stood at 3198.55% for Q4 2024, and its period low was 6732.55% during Q2 2025.
- Over the past 5 years, Cartesian Therapeutics' median EBT Margin value was 71.1% (recorded in 2021), while the average stood at 886.4%.
- Per our database at Business Quant, Cartesian Therapeutics' EBT Margin skyrocketed by 55776700bps in 2024 and then tumbled by -67772600bps in 2025.
- Quarter analysis of 5 years shows Cartesian Therapeutics' EBT Margin stood at 41.34% in 2021, then dropped by -19bps to 33.37% in 2022, then plummeted by -7229bps to 2379.12% in 2023, then surged by 234bps to 3198.55% in 2024, then plummeted by -235bps to 4318.14% in 2025.
- Its last three reported values are 4318.14% in Q3 2025, 6732.55% for Q2 2025, and 1806.73% during Q1 2025.